Streetbeat News

Regulatory

COCH

Envoy Medical has been awarded a new patent for a recharge system used with implantable batteries, enhancing their portfolio in developing fully implanted hearing devices.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:08 pm

SHPH

Shuttle Pharmaceuticals has expanded its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment to two additional sites, totaling four centers ready for patient enrollment. The participating centers are UVA Cancer Center, John Theurer Cancer Center, AHN Cancer Institute, and Miami Cancer Institute.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:03 pm

TTOO

T2 Biosystems has received FDA clearance to market its T2Candida Panel for pediatric patients. This is the only test that can detect sepsis-causing Candida species directly from blood in 3-5 hours without the need for a blood culture. The panel can detect five Candida species responsible for 95% of U.S. bloodstream infections.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:02 pm

ZNTL

The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing the company to resume enrollment in all ongoing clinical trials. This decision follows a comprehensive safety assessment after two deaths in a previous study. Zentalis plans to present further data later this year and remains on track with its 2024 data guidance.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 1:00 pm

USO

Iran's President Pezeshkian has declared that Tehran will not abandon its missile program, emphasizing its role as a deterrent. This stance may influence geopolitical tensions and impact global oil markets.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:00 pm

GEVO

Gevo has secured a U.S. patent for its Ethanol to Olefins (ETO) process, enhancing its intellectual property in bio-based renewable fuel and chemical production. The patent includes proprietary catalyst combinations designed to improve cost efficiency and yields.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:56 pm

ISPC

Trading for ISPC was halted and then resumed, with updates provided at 8:55 AM ET. The halt was likely due to pending news or significant market activity.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:55 pm

KORE

KORE Group has received a non-compliance notice from the NYSE for not meeting the $50 million average global market capitalization and stockholders' equity threshold over 30 consecutive trading days.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:54 pm

EBS

GOVX

MRNA

The US government is committed to controlling the Mpox outbreak, which may impact companies involved in vaccine development and distribution.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:49 pm

EXEL

Exelixis, Inc. announced final results from the Phase 3 CABINET study, showing cabozantinib significantly improves progression-free survival in advanced neuroendocrine tumors. These results support a supplemental New Drug Application with the FDA.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:47 pm